Through real-time fluorescent qPCR and next-generation sequencing (NGS) technologies in combination with data platforms, Luye Diagnostics provides clinical, intelligent, complete solutions in different stages of the disease.

Advanced Molecular Diagnostics

Vela Diagnostics, a member of Luye Diagnostics, is a  world leading provider of integrated molecular solutions for the diagnosis. Vela pioneer in offering both qPCR and NGS, there’re over 30 CE-IVD and TGA  tests including the first NGS test for HIV drug resistance.



Automated PCR and ngs integration workflow

Fully automated NGS workflows from nucleic acid extraction, library prep, sequencing to bioinformatics analysis and report generation with simple, standardized and reliable results

Real-time fluorescent qPCR/POCT: Convenient, efficient and accurate molecular testing

Integrated molecular diagnosis solutions for multiple diseases, helping clinical precise treatment

Real-time fluorescent qPCR

Next-generation sequencing (NGS)

Pathogen related diseases

Virus typing and drug resistance testing for infectious diseases: Multiple reports per test, 48 hours of TAT, and automated results reporting

Testing of respiratory & intestinal pathogens, transplantation-related viruses, etc. Fast and wide coverage, providing help for the accurate diagnosis and treatment of pathogen-related diseases


Digital pathology platform: Providing systematic and standardized pathological testing and analysis services by integrating pathological image scanning, cloud data storage and AI analysis

72 genetic mutations linked to breast cancer: A molecular diagnostic system suitable for the molecular typing, prognosis and immunity evaluation of Chinese breast cancer patients

Global Presence


Global Reach

Operation, service and support networks across North America, Europe, and APAC

Market Access

Regulatory approval in the United States, Europe, the Middle East, Asia Pacific and Africa, which facilitates rapid expansion. The Chinese market is expected to grow further in the next few years.

Contributing to Global COVID-19 Testing